Catabasis to Present MoveDMD Trial Data of Edasalonexent for Duchenne at Conference
Catabasis Pharmaceuticals will present results from Part B of the MoveDMD trial of edasalonexent (CAT-1004) for the treatment of Duchenne muscular dystrophy (DMD). According to a press release, the presentation, “MoveDMD: Phase 1/2 trial of Edasalonexent, an NF-kB Inhibitor, in 4- to 7-Year-Old Patients with Duchenne Muscular…